Potent, synergistic inhibition of Staphylococcus aureus upon exposure to a combination of the endopeptidase lysostaphin and the cationic peptide ranalexin

Journal of Antimicrobial Chemotherapy

Volumn 59, Issue 4, 2007, Pages 759-762

  Graham, Shirley ^a   Coote, Peter J ^a  

^a UNIVERSITY OF ST ANDREWS   (United Kingdom)

Author keywords

Antimicrobial peptides; Dermaseptin S3; Magainin 2; MRSA

Indexed keywords

AGAR; DERMASEPTIN; LYSOSTAPHIN; MAGAININ 2; METICILLIN; RANALEXIN; VANCOMYCIN; ANTIINFECTIVE AGENT; CYCLOPEPTIDE;

ANIMAL CELL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COUNT; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIFFUSION; DRUG EFFICACY; DRUG EXPOSURE; DRUG POTENCY; DRUG POTENTIATION; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; GROWTH INHIBITION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; OPTICAL DENSITY; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS SANGUINIS; WOUND DRESSING; WOUND INFECTION; BACTERIUM; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; MICROBIOLOGICAL EXAMINATION;

ANTI-BACTERIAL AGENTS; BACTERIA; DRUG SYNERGISM; LYSOSTAPHIN; MICROBIAL SENSITIVITY TESTS; PEPTIDES, CYCLIC; STAPHYLOCOCCUS AUREUS;

EID: 34250029920     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl539     Document Type: Article

References (10)

1. Clark D, Durrell S, Lee Maloy W et al. A novel antimicrobial peptide from Bullfrog (Rana catesbeiana) skin, structurally related to the bacterial antibiotic, polymyxin. J Biol Chem 1994; 269: 10849-55.
2. Giacometti A, Cirioni O, Barchiesi F et al. In-vitro activity and killing effect of polycationic peptides on methicillin-resistant Staphylococcus aureus and interactions with clinically used antibiotics. Diag Microbiol Infect Dis 2000; 38: 115-18.
3. Giacometti A, Cirioni O, Ghiselli R et al. Efficacy of polycationic peptides in preventing vascular graft infection due to Staphylococcus epidermidis. J Antimicrob Chemother 2000, 46: 751-6.
4. Browder H, Zygmunt W, Young J et al. Lysostaphin: Enzymatic mode of action. Biochem BioPhys Res Comm 1965; 19: 383-9.
5. Kusuma C, Kokai-Kun J. Comparison of four methods for determining lysostaphin susceptibility of various strains of Staphylococcus aureus. Antimicrob Agents Chemother 2005; 49: 3256-63.
6. Polak J, Della Latta P, Blackbum P. In vitro activity of recombinant lysostaphin-antibiotic combinations toward methicillin-resistant Staphylococcus aureus. Diagn Microbiol Infect Dis 1993; 17: 265-70.
7. Yan H, Hancock R. Synergistic interactions between mammalian antimicrobial defence peptides. Antimicrob Agents Chemother 2001; 45: 1558-60.
8. Climo M, Ehlert K, Archer G. Mechanism and suppression of lysostaphin resistance in oxacillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2001; 45: 1431-7.
9. Zasloff M. Magainins, a class of antimicrobial peptides from Xenopus skin: Isolation, characterisation of two active forms, and partial cDNA sequence of a precursor. Proc Natl Acad Sci USA 1987; 84 5449-53.
10. Mor A, Hani K, Nicolas P. The vertebrate peptide antibiotics dermaseptins have overlapping structural features but target specific microorganisms. J Biol Chem 1994; 269: 31635-41.